After careful review, the ADITEC Steering Committee decided to approve Abera’s proposal for a challenge study. The proposal from Abera covered challenge studies for the TB-candidates developed based on the company’s proprietary platform.
– We are very excited about the upcoming studies and we are happy to see that the committee has seen the potential in our TB-candidates. It validates the quality of the research that has gone into developing these candidates. – Prof. Joen Luirink, CSO at Abera Bioscience.
ADITEC is a collaborative research programme, funded by the EU 7th Framework Programme, that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries and 42 research partners collaborate in the ADITEC project. ADITEC comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. Different aspects of vaccination, from basic research, new technologies to clinical trials and public health, are covered. Aditec is a 5-year project funded by the European Union’s Seventh Programme for research and technological development.